Next Article in Journal
Review and Comparison of Cancer Biomarker Trends in Urine as a Basis for New Diagnostic Pathways
Next Article in Special Issue
Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials
Previous Article in Journal
The PI3K/AKT/mTOR and CDK4/6 Pathways in Endocrine Resistant HR+/HER2− Metastatic Breast Cancer: Biological Mechanisms and New Treatments
Previous Article in Special Issue
Trends in Overall Survival and Treatment Patterns in Two Large Population-Based Cohorts of Patients with Breast and Colorectal Cancer
 
 
Article

Article Versions Notes

Cancers 2019, 11(9), 1243; https://doi.org/10.3390/cancers11091243
Action Date Notes Link
article xml file uploaded 24 August 2019 12:45 CEST Original file -
article xml uploaded. 24 August 2019 12:45 CEST Update -
article pdf uploaded. 24 August 2019 12:45 CEST Version of Record https://www.mdpi.com/2072-6694/11/9/1243/pdf-vor
article xml file uploaded 28 August 2019 11:13 CEST Update -
article xml uploaded. 28 August 2019 11:13 CEST Update https://www.mdpi.com/2072-6694/11/9/1243/xml
article pdf uploaded. 28 August 2019 11:13 CEST Updated version of record https://www.mdpi.com/2072-6694/11/9/1243/pdf
article html file updated 28 August 2019 11:15 CEST Original file -
article html file updated 13 February 2020 12:21 CET Update -
article html file updated 20 July 2022 04:39 CEST Update https://www.mdpi.com/2072-6694/11/9/1243/html
Back to TopTop